David A. Siegel Rapt Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 705,000 shares of RAPT stock, worth $620,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares

705,000

Previous 698,400 0.95%

Holding current value

$620,400

Previous $2.13 Million 33.47%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.76 - $3.75 $11,616 - $24,750	6,600 Added 0.95%	705,000 $1.42 Million
Q2 2024 Aug 14, 2024	BUY	$2.89 - $9.38 $1.03 Million - $3.34 Million	355,900 Added 103.91%	698,400 $2.13 Million
Q1 2024 May 15, 2024	BUY	$6.87 - $26.45 $1.91 Million - $7.37 Million	278,500 Added 435.16%	342,500 $3.08 Million
Q4 2023 Feb 14, 2024	BUY	$11.28 - $25.46 $55,272 - $124,754	4,900 Added 8.29%	64,000 $1.59 Million
Q3 2023 Nov 14, 2023	SELL	$16.34 - $24.66 $810,464 - $1.22 Million	-49,600 Reduced 45.63%	59,100 $982,000
Q2 2023 Aug 14, 2023	SELL	$16.06 - $21.61 $163,812 - $220,422	-10,200 Reduced 8.58%	108,700 $2.03 Million
Q1 2023 May 15, 2023	SELL	$17.19 - $30.8 $316,296 - $566,720	-18,400 Reduced 13.4%	118,900 $2.18 Million
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $9,768 - $14,760	600 Added 0.44%	137,300 $2.72 Million
Q3 2022 Nov 14, 2022	SELL	$17.96 - $30.46 $818,976 - $1.39 Million	-45,600 Reduced 25.01%	136,700 $3.29 Million
Q2 2022 Aug 15, 2022	SELL	$10.26 - $23.59 $189,810 - $436,415	-18,500 Reduced 9.21%	182,300 $3.33 Million
Q1 2022 May 16, 2022	SELL	$17.02 - $40.22 $459,540 - $1.09 Million	-27,000 Reduced 11.85%	200,800 $4.42 Million
Q4 2021 Feb 14, 2022	SELL	$29.5 - $39.5 $678,500 - $908,500	-23,000 Reduced 9.17%	227,800 $8.37 Million
Q3 2021 Nov 15, 2021	BUY	$29.86 - $39.47 $3.83 Million - $5.06 Million	128,200 Added 104.57%	250,800 $7.79 Million
Q2 2021 Aug 16, 2021	BUY	$17.99 - $40.02 $1.16 Million - $2.58 Million	64,500 Added 111.02%	122,600 $3.9 Million
Q1 2021 May 17, 2021	BUY	$16.0 - $24.46 $411,200 - $628,622	25,700 Added 79.32%	58,100 $1.29 Million
Q4 2020 Feb 16, 2021	BUY	$15.89 - $40.87 $409,962 - $1.05 Million	25,800 Added 390.91%	32,400 $640,000
Q3 2020 Nov 16, 2020	BUY	$21.6 - $37.5 $142,560 - $247,500	6,600 New	6,600 $213,000

Others Institutions Holding RAPT

# of Institutions

104

Shares Held

27.1M

Call Options Held

26.7K

Put Options Held

2.4K

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $26.1M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account